The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a trastuzumab-based regimen.
Efficacy was evaluated in the multicenter, open-label, randomized DESTINY-Gastric01 trial (ClinicalTrials.gov Identifier: NCT03329690) in patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed